Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight: insights from the ARISTOTLE trial
SH Hohnloser, M Fudim, JH Alexander, DM Wojdyla… - Circulation, 2019 - Am Heart Assoc
Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight: Insights from the ARISTOTLE Trial
SH Hohnloser, M Fudim, JH Alexander, DM Wojdyla… - Circulation, 2019 - duo.uio.no
Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
SH Hohnloser, M Fudim, JH Alexander, DM Wojdyla… - Circulation, 2019 - europepmc.org
Background Guidelines caution against the use of non-vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight: Insights From the ARISTOTLE Trial
SH Hohnloser, M Fudim, JH Alexander, DM Wojdyla… - Circulation, 2019 - diva-portal.org
BACKGROUND: Guidelines caution against the use of non-vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (= 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (= 60 kg) body weight …
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
SH Hohnloser, M Fudim, JH Alexander, DM Wojdyla… - Circulation, 2019 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Guidelines caution against the
use of non–vitamin K antagonist oral anticoagulants in patients with extremely high (> 120 …
use of non–vitamin K antagonist oral anticoagulants in patients with extremely high (> 120 …
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
SH Hohnloser, M Fudim, JH Alexander, DM Wojdyla… - Circulation, 2019 - Am Heart Assoc
BACKGROUND: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
SH Hohnloser, M Fudim, JH Alexander… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Guidelines caution against the use of non-vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
[PDF][PDF] Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
SH Hohnloser, M Fudim, JH Alexander… - Circulation, 2019 - scholar.archive.org
BACKGROUND: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …